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This supplement also contains articles that de- 
scribe the broad experience with terazosin in ad- 
dressing issues in hypertension. The pharmacokinet- 
its of this agent are described as well as its clinical 
applications. Its efficacy has been examined carefully 
in differing racial groups, and considerable data have 
also been accumulated on its safety profile. Terazosin 
has been found to be effective in both combination 
therapy and monotherapy for the treatment of hy- 
pertension, and these experiences are described in 
this supplement. 
In summary, these proceedings comprise a series of 
articles that address the modern concept of hyper- 
tension and provide a broad basis for understanding 
and treating this very interesting condition. Al- 
though decreasing blood pressure is a pivotal part of 
treating hypertensive patients, other issues must also 
be considered. The selective CYI -adrenergic-blocking 
agent terazosin is now being examined in this con- 
text, and these reports should help to position this 
agent as an important part of the armamentarium to 
be used in achieving our treatment goal of protecting 
hypertensive patients from major cardiovascular 
events. 
Clinical implications of pathophysiologic 
changes in the midlife hypertensive patient 
Both aging and hypertension decrease cardiac output through a lower stroke volume and a 
diminished fi-adrenergic responsiveness. In parallel, the vascular resistance increases because of 
vascular hypertrophy. In addition, in hypertension the cu-adrenergic responsiveness is enhanced. 
Aging and hypertension are also assocfated with an Increase in plasma cholesterol and insulin 
values. These alterations in cholesterol and insulin levels become particularly pronounced in 
middle-aged patients with hypertension. a-Adrenergic-blocking agents have a positive effect on 
ltpids and insulin resistance. The shift toward enhanced a-adrenergic responsiveness, and the 
fact that vasodilators do not diminish exercfse performance favor the use of cr-blockers as a first 
drug in middle-aged patients with hypertension. Blood pressure lowering still remains the 
paramount goal, and these compounds should be used only if proved to be efficacious in a given 
individual patient. (AM HEART J 1991;122:886-91.) 
Stevo Julius, MD, ScD Ann Arbor, Mich. 
Both hypertension and aging elicit similar cardio- 
vascular changes. The difference is in the time course: 
slower with aging, faster with hypertension. The pace 
of cardiovascular changes is particularly accelerated 
when both conditions coexist. It is important to un- 
derstand that aging and hypertension are dynamic 
processes. Consequently, determining which patho- 
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physiologic changes are present in an individual pa- 
tient may affect clinical decisions. 
It is not difficult to visualize why hypertension and 
aging affect the circulation in a similar fashion; the 
overall wear and tear on the vessels and the heart 
might be similar if they were exposed to lower blood 
pressure over a longer period or to a higher pressure 
over a shorter period of time. However, the similar- 
ity between hypertension and aging extends beyond 
their immediate effects on circulatory organs. Both 
conditions are associated with hyperlipidemia and 
insulin resistance. The nature of this association is 
not clear, but in practical terms the frequent pres- 
ence of metabolic abnormalities in middle-aged hy- 
pertensive subjects is clinically important. This arti- 
Volume 122 
Number 3. Part 2 Age-related pathophysiologic alterations 887 








RR RS 400 800 
Oxygen Consumption (ml 1 min) STPD 
Fig. 1. Effect of exercise on the calculated total peripheral resistance in three age groups. The oxygen 
consumption is given at STPD conditions (standard temperature, pressure, dry). (Modified from Julius S, 
Amery A, Whitlock LS, Conway J. Influence of age on the hemodynamic response to exercise. Circulation 
1967;36:222-30, by permission of The American Heart Association, Inc.) 
cle describes the age- and blood pressure-dependent 
changes in cardiovascular function and how they may 
affect the choice of antihypertensive agents. A case 
will be made for the use of a-blocking agents in mid- 
dle-aged patients with hypertension. 
CHANGES IN STROKE VOLUME AND VASCULAR 
RESISTANCE 
Assessment by proper invasive hemodynamic 
methods shows that the cardiac output and stroke 
volume decrease with age. l-3 One study that found a 
normal cardiac output and an increased stroke vol- 
ume in elderly subjects used radionuclide mea- 
surements.4 The authors claim that this aberrant 
finding reflects their selection of particularly healthy 
study subjects. However, radionuclide measurements 
of cardiac output in elderly subjects are not reli- 
able. 
Decreased cardiac output in elderly persons is fre- 
quently associated with an age-dependent blood 
pressure elevation. The hemodynamic end result of 
these trends in blood pressure and cardiac output is 
an increase in systemic vascular resistance with 
aging. Despite the intense stimulus to vasodilate, 
elderly subjects continue to show increased vascular 
resistance during all levels of exercise.’ This finding 
suggests that the increased resistance in elderly per- 
sons is caused by structural changes in the vessels. If 
the increased vascular resistance at rest were just a 
reflex response to the lower cardiac output, strong 
vasodilation during exercise should override the 
resting vasoconstriction. 
In subjects of similar age, the stroke volume and 
cardiac output decrease and vascular resistance in- 
creases with increasing blood pressure levels.5 These 
effects of blood pressure are identical to the effects of 
aging. Studies in hypertension, however, have shed 
some light on the mechanism of these changes. The 
decrease in stroke volume appears very early in hy- 
pertension. During exercise, patients with hyperten- 
sion respond like elderly subjects: at each level of ex- 
ercise the vascular resistance progressively decreases 
but remains relatively elevated compared with that 
of control subjects6 (Fig. 1). Despite this progressive 
fall in resistance, stroke volume remains lower than 
in control subjects and reaches a plateau at lower ex- 
ercise loads.7 If the higher afterload caused by higher 
resistance is the reason for the decreased stroke vol- 
ume in hypertension, then during exercise as the re- 
sistance progressively decreases, the stroke volume 
should eventually become comparable with that ob- 
served in normotensive subjects. Exercise results 
then suggest that the limitation of the stroke volume 
is intrinsic to the heart. Lund-Johansen’s work7 
demonstrates that such changes are already present 
in very mild forms of hypertension. 
Our work provides additional information about 
the nature of the limitation in stroke volume.8 
Patients with hypertension have faster heart rates, 
which conceivably could be the reason for the lower 
calculated stroke volume. This is not the case. After 
a pharmacologic blockade of the sympathetic and 
parasympathetic afferents to the heart, the heart 
rates of both normotensive subjects and patients with 
borderline hypertension are identical but the stroke 
volume of the latter remains substantially de- 
creased.8 
What is the mechanism of this decrease in stroke 
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volume? As already discussed, higher afterload is not 
the likely cause; stroke volume remains decreased 
even when afterload is substantially diminished 
through the physiologic vasodilation of exercise. Our 
studies suggest that a decrease in cardiac compliance 
is the major reason for the decrease in stroke volume 
in patients with mild hypertension. The evidence is 
indirect; cardiac compliance cannot be readily mea- 
sured. Venous return is not impaired in hypertension. 
Cardiopulmonary blood volume, an excellent index 
of venous filling, is not decreased in hypertension. In 
fact, an increase has been found in the very early 
phases of borderline hypertension.g, lo As hyperten- 
sion advances, cardiopulmonary blood volume re- 
turns to the normal range and stroke volume falls.” 
These findings suggest that the hearts of hyperten- 
sive patients become stiffer (less compliant) and fail 
to stretch sufficiently in response to normal venous 
filling. The earliest clinical sign of this altered com- 
pliance is the Sq sound in patients with advanced hy- 
pertension. Modern echo-Doppler methods have re- 
vealed a diastolic filling abnormality during the very 
early phases of hypertension.12-l4 
Whereas decreased cardiac compliance is the prox- 
imate mechanism for the lower stroke volume in hy- 
pertension, the increased afterload is its primary 
cause. Chronic blood pressure elevation causes not 
only myocardial hypertrophy; a decrease in the car- 
diac compliance is one of the earliest manifestations 
of hypertension. 
ALTERED CARDIAC AND VASCULAR 
RESPONSIVENESS 
The autonomic control of the circulation depends 
on the relationship between the centrally generated 
tone and the peripheral responsiveness to that tone. 
Hypertension and aging alter the cardiovascular re- 
sponsiveness to sympathetic stimulation. 
Infusions of the fl-adrenergic agonist isoproterenol 
cause smaller increases in heart rate and cardiac out- 
put in hypertensive patients than in normotensive 
subjects83 l5 fl-Adrenergic-mediated vasodilation is 
also diminished in hypertension.16 Similar decreases 
in P-adrenergic responsiveness of the hearti l8 and 
blood vessels have been observed with aging.lg At the 
biochemical level, aging diminishes @-adrenergically 
stimulated generation of adenyl cyclase.20y 21 With 
aging, both a decreased number of @-adrenergic 
receptors (down-regulation) and an uncoupling be- 
tween the receptors and their second messenger2’ 
seem to be at play. 
Increased a-adrenergic responsiveness is a well- 
documented phenomenon in hypertension.23, 24 A 
similar age-related enhanced responsiveness of CX- 
adrenergic receptors has not been reported. In fact it 
has been suggested that the pressure response to G- 
adrenergic stimulation is decreased with aging25 be- 
cause of an uncoupling between the receptor and its 
biochemical mediator similar to that reported for p- 
receptors. 
The nature of the ar-adrenergic hyperreactivity in 
hypertension has not been fully elucidated. There is 
no doubt that vascular hypertrophy is a major 
factor,26 but a specific hypersensitivity of receptors 
and calcium-mediated a-adrenergic contraction may 
also play a role. 24 From a practical standpoint, it is 
important to understand the amplifying role of arte- 
riolar hypertrophy. This concept has been champi- 
oned and studied in detail by Folkow.27 In the course 
of hypertension, resistance vessels respond to the in- 
crease in work load with a hypertrophy of their me- 
dial, muscular layer. The thicker medial layer en- 
croaches on the lumen of the vessel, particularly 
during vasoconstriction. Vascular resistance is a 
fourth power function of the vessel’s lumen. Even 
minor increases in wall thickness greatly amplify 
vascular resistance during vasoconstriction. Higher 
pressure is required to overcome the increased resis- 
tance, which sets the stage for a vicious cycle of 
worsening hypertension. More pressure begets more 
hypertrophy, which in turn necessitates further in- 
creases in blood pressure. Folkow’s postulate ex- 
plains why hypertension is a progressive disease and 
why early treatment is mandatory to break the 
vicious cycle. 
Since physical properties of a hypertrophic vessel 
are the reason for its increased reactivity, such a ves- 
sel should be overresponsive to all vasoconstrictive 
stimuli. In our experiments increased responses to 
norepinephrine and angiotensin have been ob- 
served,26 but other investigators have found in- 
creased responses only to a-adrenergic stimu- 
lation. 23. 24 Therefore it is possible that the enhanced 
a-adrenergic responsiveness in hypertension is a 
combination of a specific a-adrenergic hypersensi- 
tivity and a nonspecific enhancement of reactivity 
caused by vascular hypertrophy. Of importance, the 
structural component of this enhanced a-adrenergic 
responsiveness in hypertension may in itself be 
dependent on the prevailing sympathetic tone. It is 
now accepted that sympathetic stimulation is one of 
the “trophic” factors independent of the blood pres- 
sure that in their own right favor cardiovascular 
hypertrophy.2s The trophic effect of sympathetic 
stimulation on cardiac myocytes is mediated through 
a-adrenergic receptors. 29 The sympathetics may also 
play a role in the development of vascular hypertro- 
phy in hypertension. In our studies, the minimal 
forearm vascular resistance (a measure of vascular 
hypertrophy) has been positively correlated with 
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plasma norepinephrine levels.30 It is also well docu- 
mented that the sympathetic drive is frequently 
elevated in hypertension. 31 This elevation is partic- 
ularly characteristic of younger patients with mild 
forms of hypertension.32l 33 , 
In summary, a vicious cycle leads to a progressive 
elevation of vascular resistance in the course of 
hypertension. Vascular hypertrophy enhances Q- 
adrenergic responsiveness, and enhanced sym- 
pathetic tone may favor further vascular hyper- 
trophy. 
METABOLIC ABNORMALITIES 
Treatment of hypertension greatly improves the 
prognosis in regard to strokes and congestive heart 
failure but has little effect on the excessive coronary 
morbidity. 34 This paradox, that high blood pressure 
is associated with excessive coronary heart disease 
but blood pressure lowering does not reduce the cor- 
onary morbidity, is frequently explained by the neg- 
ative effect of diuretics and &blocking agents on pa- 
tients’ lipid profiles. The evidence to support this 
explanation is weak and inferential. Almost entirely 
forgotten in the dilemma is the fascinating associa- 
tion between hypertension and coronary risk factors. 
There is no doubt that high blood pressure per se 
causes atherosclerosis; after coronary bypass surgery, 
atherosclerosis-free veins that are placed in the 
high-pressure circuit soon develop atherosclerosis. 
However, in addition to excess atherosclerosis be- 
cause of higher pressure, patients with hypertension 
have several independent risk factors that in their 
own right are conducive to atherosclerosis. Dyslipid- 
emias and hyperinsulinemia are found in a large pro- 
portion of patients with hypertension.35p 36 Hyper- 
insulinemia is an independent risk factor for athero- 
sclerosis.37 A recent study conducted in Tecumseh, 
Mich., sheds further light on this relationship.38 
Middle-aged subjects (average age 31 years) with 
borderline hypertension had significantly elevated 
levels of cholesterol, triglycerides, and insulin and an 
increased insulin/glucose ratio, whereas their low- 
density lipoprotein cholesterol level was significantly 
decreased. The relationship between the systolic 
blood pressure and coronary risk factors was also seen 
in the overall population of normotensive subjects. 
This relationship, to a large degree, reflected the as- 
sociation between overweight and blood pressure. 
Overweight, in turn, becomes more of a problem with 
increasing age. For example, in Tecumseh overweight 
became a noticeable correlate of the blood pressure 
only after puberty.38 
The similarity between the effects of hypertension 
and aging on plasma lipids and plasma insulin levels 
is also fascinating. Cholesterol and insulin levels 
increase with age. Middle-aged patients with hy- 
pertension are more likely to show lipid abnor- 
malities and may have the first signs of insulin resis- 
tance. The nature of the association of aging and 
hypertension with hyperinsulinemia is not yet un- 
derstood, but some useful hints come from the results 
of treatment of hypertension. Only two categories of 
drugs are known to actually improve insulin resis- 
tance: a-adrenergic-blocking agents3g and convert- 
ing enzyme inhibitors. 4o Both are vasodilators. It is 
reasonable to speculate that hypertension and aging 
may decrease the blood supply to a tissue critical for 
insulin’s effect on glucose and that vasodilation may 
improve it. 
CLINICAL IMPLICATIONS 
Treatment of hypertension is entirely empiric. 
Antihypertensive compounds are developed in chem- 
ical laboratories, tested in efficacy trials, and then 
released for practical use. The primary goal is to 
lower the blood pressure regardless of the underlying 
cause of hypertension. Before the advent of the sec- 
ond generation of antihypertensive compounds, all 
sympatholytic agents caused fluid retention, and 
vasodilators could not be used without sympatholytic 
agents to buffer the reflex activation of the sympa- 
thetics. Therefore uniform stepped care treatment of 
hypertension was devised, starting with diuretics, 
adding sympatholytics, and finally, if needed, vasodi- 
lators. Although this approach has yielded impres- 
sive results in reducing the morbidity and mortality 
of hypertension, it is intellectually unsatisfactory. 
One would like to have some firm system for choos- 
ing an antihypertensive compound in a given patient. 
How can a physician defend the decision to use one 
drug rather than another similar drug? The proposed 
solutions usually take into account one of three possi- 
ble criteria: demographics, pathophysiology, or claim 
of a specific advantage beyond antihypertensive 
efficacy. Certain drugs have been recommended for 
young versus old, black versus white, and overweight 
versus normal-weight persons. Pathophysiologic clas- 
sification into volume versus vasoconstriction types 
of hypertension is an example of a pathophysiologic 
approach to the choice of antihypertensive agents. 
An example of a claimed specific advantage of an anti- 
hypertensive drug is the recent suggestion that con- 
verting enzyme inhibitors offer better protection 
against renal failure in hypertensive diabetic pa- 
tients. All these approaches rest on a good rationale, 
and some of them are supported by actual experi- 
mental results. However, the clinical advantage of 
these recommendations need not be overemphasized. 
Exceptions to the proposed rules abound. The 
achievements of stepped care treatment of hyper- 
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tension are considerable, and new approaches, while Because both aging and hypertension are inti- 
intellectually appealing, should not divert the focus mately associated with dyslipidemia and insulin re- 
from the need to achieve a normal blood pressure. sistance, it is very important to determine whether a 
The primary goal of antihypertensive therapy is still middle-aged patient with hypertension has these 
to lower the blood pressure. Only if that goal is coronary risk factors. Diuretics and P-blocking agents 
achieved can one engage in matching the patient with tend to have a negative effect on plasma lipid levels 
the specific drug. Consequently, while marshalling and should not be used in patients with dyslipid- 
pathophysiologic evidence that generally favors the emias. Whereas calcium antagonists and converting 
use of vasodilators, particularly a-adrenergic vaso- enzyme inhibitors are lipid neutral, a-adrenergic- 
dilators, in middle-aged patients with hypertension, blocking agents actually cause a modest decrease in 
I do not wish to overstate the case. If an cY-adrener- plasma lipid levels. 41-4’1 New findings of an improve- 
gic-blocking agent is efficacious, and this is fre- ment in insulin sensitivity in patients treated with 
quently the case, it is well suited for use in middle- converting enzyme inhibitors and with an a-adren- 
aged patients with hypertension. ergic-blocking agent3g, JO are promising. 
The circulatory effects of hypertension and aging 
are similar, and the hemodynamics of a middle-aged 
patient with hypertension are akin to those of an 
older, normotensive person. Such a patient has 
elevated vascular resistance at rest, is not able to 
vasodilate sufficiently during physical exercise, and 
has a fixed decrease in stroke volume. The sympa- 
thetic tone has shifted from a less-responsive heart to 
more-responsive resistance vessels. This increased 
dependence of the vascular resistance on the prevail- 
ing cu-adrenergic tone suggests that lowering blood 
pressure with a-adrenergic-blocking agents is an 
appropriate pathophysiologic intervention in such 
patients. The growing evidence that sympathetic 
stimulation through an a-adrenergic trophic effect 
enhances cardiac hypertrophyZg further speaks for 
the use of a-adrenergic-blocking agents in middle- 
aged patients. Vascular hypertrophy is an important 
amplifying mechanism in hypertension. If it is left 
unattended, the progressive vascular hypertrophy 
leads to more vascular resistance, increased respon- 
siveness to all vasoconstrictive stimuli, and worsen- 
ing of the blood pressure.” 
Specific clinical trials are needed to see whether 
the theoretic advantages of a-adrenergic blockers can 
be translated into a positive clinical effect. In addi- 
tion, the fact that some antihypertensive drugs 
improve the underlying metabolic abnormality is of 
great scientific interest. It may be possible to use (Y- 
adrenergic-blocking agents, converting enzyme in- 
hibitors, and other vasodilators as research tools to 
unravel the relationship between hypertension and 
insulin resistance. If the common denominator is the 
hemodynamic action of vasodilators, then studies of 
patterns of regional vasodilation versus the effect on 
insulin sensitivity may be very useful. Analysis of the 
few studies in the literature suggests that c-ui-adren- 
ergic-blocking agents may have a more potent effect 
on insulin resistance than do other compounds. If 
this finding is replicated in other studies, an addi- 
tional relationship between the sympathetic overac- 
tivity in hypertension and the development of insu- 
lin resistance may be postulated. 
On a practical level, it is very important to lower 
the blood pressure in a middle-aged patient with 
drugs that do not negatively affect exercise perfor- 
mance. Physical exercise is an adjuvant to weight 
control, improves insulin resistance, and contributes 
to the patient’s feeling of well-being. Unless a mid- 
dle-aged person makes a conscious effort to exercise 
regularly, a growing family, increasing business re- 
sponsibilities, and the loss of former recreational 
partners are likely to decrease the amount of exercise 
obtained. Adding antihypertensive agents that cause 
fatigue or cramps further discourages exercise. Be- 
cause they do not diminish the exercise capacity, 
converting enzyme inhibitors, calcium antagonists, 
and a-adrenergic-blocking agents are preferred over 
P-blocking agents and diuretics in most middle-aged 
patients with hypertension. 
In conclusion, age- and hypertension-related car- 
diovascular and metabolic changes provide a good 
rationale for the use of a-adrenergic-blocking agents 
in middle-aged patients with hypertension. Some of 
the advantages of al-blockade, such as a positive ef- 
fect on blood lipid levels and the absence of negative 
effects on exercise performance, are sufficiently 
proved and deserve to be incorporated into the ther- 
apeutic decision. Other advantages are still specula- 
tive. Nevertheless, if an a-adrenergic-blocking agent 
causes no side effects and induces a good blood pres- 
sure response, it should be a preferred treatment for 
a middle-aged subject with hypertension. 
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